Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haffner, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haffner, S. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 16, Issue 5 835-840, Copyright © 1993 by American Diabetes Association

ARTICLES

Lipoprotein(a) and diabetes. An update

SM Haffner
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7873.

On the basis of the available data (much of which is contradictory), I suggest that the following might summarize the role of Lp(a) in diabetes currently. 1. Lp(a) in IDDM: Concentrations are probably elevated. Concentrations are probably related to metabolic control. Concentrations are increased with microalbuminuria. 2. Lp(a) in NIDDM: Concentrations are not elevated. Concentrations do not change with metabolic control. Too few data exist to make an assessment of relation of Lp(a) to microalbuminuria in NIDDM. 3. Lp(a) and CHD in diabetes: Little current evidence shows that Lp(a) is a risk factor for CHD in diabetes. More studies--especially prospective studies with larger numbers of subjects--need to be done.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
C. Gazzaruso, A. Garzaniti, S. Giordanetti, C. Falcone, E. De Amici, D. Geroldi, and P. Fratino
Assessment of Asymptomatic Coronary Artery Disease in Apparently Uncomplicated Type 2 Diabetic Patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism
Diabetes Care, August 1, 2002; 25(8): 1418 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al.
Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus
Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. L. Rainwater and S. M. Haffner
Insulin and 2-Hour Glucose Levels Are Inversely Related to Lp(a) Concentrations Controlled for LPA Genotype
Arterioscler. Thromb. Vasc. Biol., August 1, 1998; 18(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
H. Olivecrona, A. G. Johansson, E. Lindh, S. Ljunghall, L. Berglund, and B. Angelin
Hormonal Regulation of Serum Lipoprotein(a) Levels : Contrasting Effects of Growth Hormone and Insulin-Like Growth Factor–I
Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 847 - 849.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Makino, J. W. Furbee Jr, A. M. Scanu, and G. M. Fless
Effect of Glycation on the Properties of Lipoprotein(a)
Arterioscler. Thromb. Vasc. Biol., March 1, 1995; 15(3): 385 - 391.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1993 by the American Diabetes Association.